MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
about
Long non-coding RNA XIST promotes cell growth and invasion through regulating miR-497/MACC1 axis in gastric cancer.Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer.Detection of MET mRNA in gastric cancer in situ. Comparison with immunohistochemistry and sandwich immunoassays.Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil.
P2860
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
@en
type
label
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
@en
prefLabel
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
@en
P2860
P1433
P1476
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy
@en
P2093
Isamu Okamoto
P2860
P2888
P304
P356
10.1007/S10120-015-0585-X
P577
2015-12-21T00:00:00Z
P6179
1022738363